XRTX — XORTX Therapeutics Income Statement
0.000.00%
Last trade - 00:00- CA$5.92m
- CA$4.33m
Annual income statement for XORTX Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.95 | 2.91 | 10.3 | 6.05 | 4.12 |
| Operating Profit | -0.95 | -2.91 | -10.3 | -6.05 | -4.12 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.958 | -1.32 | -7.72 | -2.16 | -3.31 |
| Net Income After Taxes | -0.958 | -1.32 | -7.72 | -2.16 | -3.31 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.958 | -1.32 | -7.72 | -2.16 | -3.31 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.958 | -1.32 | -7.72 | -2.16 | -3.31 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.42 | -1.2 | -5.22 | -1.09 | -1.15 |